EP3876954A1 - Procédé d'obtention d'une fraction vasculaire stromale - Google Patents

Procédé d'obtention d'une fraction vasculaire stromale

Info

Publication number
EP3876954A1
EP3876954A1 EP20864767.7A EP20864767A EP3876954A1 EP 3876954 A1 EP3876954 A1 EP 3876954A1 EP 20864767 A EP20864767 A EP 20864767A EP 3876954 A1 EP3876954 A1 EP 3876954A1
Authority
EP
European Patent Office
Prior art keywords
fat
syringe
blades
space
transferring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20864767.7A
Other languages
German (de)
English (en)
Other versions
EP3876954A4 (fr
Inventor
Salih ÖZOVALI
Timur Veysel DO RUOK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
T Biyoteknoloji Laboratuvar Estetik Medikal Kozmetik San Tic Ltd Sti
Original Assignee
T Biyoteknoloji Laboratuvar Estetik Medikal Kozmetik San Tic Ltd Sti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Biyoteknoloji Laboratuvar Estetik Medikal Kozmetik San Tic Ltd Sti filed Critical T Biyoteknoloji Laboratuvar Estetik Medikal Kozmetik San Tic Ltd Sti
Publication of EP3876954A1 publication Critical patent/EP3876954A1/fr
Publication of EP3876954A4 publication Critical patent/EP3876954A4/fr
Pending legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/56—Labware specially adapted for transferring fluids
    • B01L3/563—Joints or fittings ; Separable fluid transfer means to transfer fluids between at least two containers, e.g. connectors
    • B01L3/5635—Joints or fittings ; Separable fluid transfer means to transfer fluids between at least two containers, e.g. connectors connecting two containers face to face, e.g. comprising a filter
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0681—Filter
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration

Definitions

  • the invention is related to a method for separating/isolating the stromal vascular fraction (SVF) located in the fat cells of mammals, particularly humans, from other components that they are naturally together with.
  • SVF stromal vascular fraction
  • Stem cells are ideal sources to develop regenerative components for the body.
  • the stem cells located in the human body are limited in number, and various protocols are already being developed, in order to exactly optimize the separation/isolation and usage efficiencies of said stem cells.
  • SVF stromal vascular fraction
  • the suitable incubation medium conditions must be obtained to perform collagenase digestion. This medium is provided by using extremely expensive incubation devices that have been customized for said process to be carried out. Besides this, as collagenase is a toxic material for humans, it needs to be separated from the SVF that has been obtained. In order to perform said separation, several numbers of centrifugation, generally 5 centrifugation processes need to be carried out.
  • EP3019599B1 a method for isolating SVF has been described.
  • the fat tissue taken from the donor is broken into a single cell suspension by applying a homogenous mechanical force or by mincing and at the same time, SVF is maintained without disrupting its structure. Any kind of collagenase usage is not required during this process.
  • the quality of the SVF that is obtained is an important factor regarding the success of the process (especially surgical procedures).
  • quality mentioned here refers to the regenerative nucleated cell numbers. In the known usage fields, as the number of nucleated cells increases, improvements are observed in the results.
  • the number of nucleated cells varies between 1-1 .5 million/mL in the best results. As it can also be seen from the results in the method described in the patent document numbered EP3019599B1 , this number is approximately 1 million/mL.
  • the present invention aims to overcome the problems mentioned above and to provide a novelty in the prior art.
  • the main aim of the invention is to convey a method for separating/isolating the stromal vascular fraction (SVF) located in the adipose tissue of mammals, particularly humans, from other components that they are naturally together with.
  • Another aim of the invention is to provide a method that enables cheaper, safer and faster SVF separation/isolation of SVF by eliminating the dependency of using collagenase.
  • Another aim of the invention is to provide a method which not only eliminates the usage of collagenase but it also ensures to obtain SVF having a higher number of nucleated cells.
  • the present invention that is described above and that can carry out all of the aims to be construed from the detailed description below is a method of stromal vascular fraction isolation from adipose tissue.
  • the method subject to the invention comprises the steps of; obtaining a sample containing adipose tissue taken from a donor; centrifuging the sample until blood, fat and triglycerides are separated; transferring the condensed fat section into a syringe; coupling the syringe containing the fat with the fat breaking kit syringe from their ends such that the fat is transferred from one syringe to the other through the blades of the fat breaking kit, wherein it is selected for the space between said blades to be between 50-2400 microns; repeating the above-mentioned process at least 5 more times, by passing the fat from one syringe to the other through the space between the blades, and repeating this process at least one more time, wherein the blade spaces used in the fat breaking kit are smaller
  • said blade spaces are respectively 1200 and 600 microns.
  • the step of transferring fat from one syringe to the other at least 5 times through the space between the blades is repeated two more times and the blade spaces used in the fat breaking kit are selected to be smaller for every repetition.
  • said blade spaces are respectively 2400, 1200 and 600 microns.
  • said blade spaces are circular.
  • said blade spaces are pentagonal or hexagonal.
  • flaps have been provided on each side of said spaces such that they are centrifugal.
  • the step of transferring fat from one syringe to the other comprises the process to be repeated at least 9 times where fat is transferred through the space between the blades.
  • the step of transferring fat from one syringe to the other comprises the process to be repeated at least 15 times where fat is transferred through the space between the blades.
  • the step of transferring fat from one syringe to the other comprises the process to be repeated at least 19 times where fat is transferred through the space between the blades.
  • the step of transferring fat from one syringe to the other comprises the process to be repeated at least 25 times where fat is transferred through the space between the blades.
  • the step of transferring fat from one syringe to the other comprises the process to be repeated 31 times where fat is transferred through the space between the blades.
  • ringer lactate or normal saline is added into the fat whose process of being passed through the blades has been completed.
  • said container is a syringe.
  • the base part of said syringe is conical.
  • the stromal vascular fraction that has accumulated at the base of the container is collected by scraping with a needle.
  • the collected stromal vascular fraction is re-suspended.
  • said centrifuge processes are carried out in a swinging bucket centrifuge device.
  • said donor is a mammal. In a preferred embodiment of the invention, said donor is human.
  • Figure 1 is a flow diagram of the method of obtaining stromal vascular fraction (SVF) subject to the invention.
  • Figure 2 is the illustrative schematic view of the fat breaking and transfer kit which enables transfer from one syringe to the other.
  • Figure 2A is the view of the blade structure and the detailed view of A section in said structure.
  • the subject matter of the invention is related to a method for separating/isolating the stromal vascular fraction (SVF) located in the fat cells of mammals, particularly humans, from other components that they are naturally together with.
  • SVF stromal vascular fraction
  • FIG 1 a flow diagram of an alternative embodiment of the method of obtaining stromal vascular fraction (SVF) subject to the invention has been provided.
  • the transfer process of fat from one syringe (10) to the other syringe (10) has been shown three times.
  • two processes of transferring fat from one syringe (10) to the other (10) is also adequate to obtain the desired technical benefit.
  • the invention is a method of stromal vascular fraction separation from fat tissues, comprising the steps of obtaining a sample containing fat tissue taken from the donor; centrifuging the sample until blood, fat, and triglycerides are separated; transferring the fat section into a syringe (10); coupling the syringe (10) containing the fat with the fat breaking kit (11) syringe (10) from their ends such that the fat is transferred from one syringe (10) to the other syringe (10) through the blades (12) of the fat breaking kit (11 ), wherein it is selected for the space between said blades (121 ) to be between 50-2400 microns; repeating the above-mentioned process at least 5 more times, by passing the fat from one syringe (10) to the other through the space between the blades (121 ), and repeating this process at least one more time, wherein the blade spaces (121 ) used in the fat breaking kit (11 ) are smaller for every repetition; respectively shaking the obtained broken
  • stromal vascular fraction refers to cell fraction that is derived from the fat tissue vascular component comprising different cells.
  • the fat- derived stem cells can comprise other cells that are immune or that express one or more cells such as mesenchymal cells, hematopoietic cells, hematopoietic stem/progenitor cells, chondrocytes, osteoblasts, osteoclasts, endothelium precursor or progenitor cells, endothelial cells, included but not limited with straight muscles such as pericytes, CD34 + cells (typically found in the umbilical cord), CD29 + cells, CD166 + cells, Thy-1 + or CD90 + stem cells, CD44 + cells, monocytes, leukocytes, lymphocytes, immune cells such as B and T cells, NK cells, macrophages, dendritic cells, neutrophil leukocytes, neutrophils, eosinophils, basophils, granulocytes, erythrocytes, eos
  • said cells can comprise CD3, CD14 (macrophage marker), CD19, CD20 (B cell marker), CD29 (integrin unit), CD31 (endothelial, thrombocytes, macrophage, dendritic cell, granulocyte, T / NK cells, lymphocytes, megakaryocytes, osteoclasts, neutrophils, and others), CD44 (Hyaluronic acid receptor), CD45 (B and T cell marker), CD56, CD73 (lymphocyte differentiation marker) and CD105 markers.
  • the stromal vascular fraction can comprise cells that express any of the markers described in this description and any combination thereof.
  • the term “precursor cell” and “stem cell” can be used in substitution for each other and they refer to cells that can transform into different cell types.
  • syringe (10) refers to fat syringes (10) that are frequently used in particularly the plastic surgery sector.
  • donor refers to living beings that can provide the related fat tissues, preferably to mammals, specifically to humans as mentioned in the detailed description.
  • samples that contain fat tissue are obtained from the donor.
  • the sample is obtained using a “tumescent technique”.
  • fluid is given into the body and the fat cells that are to be extracted together with water are expanded.
  • This fluid also comprises anesthetic inputs. It is unavoidable for the sample obtained using this method to contain a little amount of said fluid.
  • the samples that are extracted are divided into suitable and preferably equal amounts and are transferred into syringes (10) or suitable container and following this, they are subjected to centrifugation.
  • the aim here is to separate the fat from the remaining sample.
  • the centrifugation process is preferably carried out using a swinging bucket type centrifuge device.
  • the sample is separated into three sections as blood, fat, and triglycerides. Besides this, if the sample is obtained using the “tumescent technique”, it is possible for the blood to contain an amount of tumescent fluid.
  • the samples obtained are centrifuged for approximately 8 minutes with a relative centrifuge force of 1500 G.
  • the amount of 40cc fat obtained from the donor is transferred into 4 suitable syringes (10) and is centrifuged.
  • blood or blood-tumescent fluid mixture
  • fat condensed fat
  • triglycerides are located at the top section.
  • the fat section located in the middle section is transferred into another syringe without being mixed with the other sections.
  • a fat breaking kit (11 ) is coupled to the end of the syringe (10) that is filled with the fat section and another syringe (10) end is coupled to the other end of the fat breaking kit (11 ). Said coupling has been given schematically in Figure 2.
  • suitable fat breaking kits (12) can be the T-Biyoteknoloji Ltd Sti. (T-Lab ®) Microlyzer ®.
  • a blade (12) Inside said fat breaking kit (12) a blade (12) has been provided that has blade spaces (121 ) such that fat can pass through.
  • An embodiment of the blade structure has been shown in Figure 2. A.
  • the blade (12) can have blade spaces (121 ) in different forms, said forms can be selected to have circular, pentagonal, or hexagonal geometry.
  • flaps (122) have been provided on each side of said blade spaces (121) such that they are centrifugal.
  • the size of said spaces can vary between 50-2400pm, particularly between 600-2400 pm.
  • the syringe (10) that is full with the fat section is pressed and the fat section is passed through the fat breaking kit (12) and is transferred into the other syringe (10) and following this, the fat is again transferred back from the second syringe (10) into the first syringe (10) by being passed through the fat breaking kit (12).
  • This process is received at least 5 more times.
  • the transfer from one syringe (10) to the other syringe (10) is counted as a process step.
  • the size of said spaces of the blades (12) can vary between 50-2400pm.
  • the blade spaces can vary between 2400-600 pm.
  • the sizes of the blade spaces (121) are particularly between 1500-600 pm, more specifically between 1200-600 pm. A blade having blade spaces (121 ) of 1200 pm has been used in the application.
  • the transferring from one syringe (10) to the other (10) can be carried out 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49 or 50 times.
  • the number of the related transfers is preferably between 25-35, however, in the assays carried out, 31 has been determined to be the optimum number.
  • the fat tissue obtained is transferred from a syringe (10) into the fat breaking kit (11 ) as it has been shown in Figure 2, by said fat tissue being passed through another fat breaking kit (11 ).
  • the blade spaces (121) of the blades (12) inside this fat breaking kit (11 ) is smaller from the blade spaces (121 ) that were used during the transfer process from one syringe (10) into the other syringe (10) at the initial stage.
  • the size of said spaces of the blades (121) can vary between 50-2400pm. Preferably the blade spaces can vary between 2400-600 pm. The sizes of the blade spaces (121 ) are particularly between 300-1500 pm, more specifically between 600-900 pm. A blade having blade spaces (121 ) of 600 pm has been used in the application.
  • the process of transferring from this second syringe (10) to the other syringe (10) can be carried out 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49 or 50 times.
  • the number of the related transfers is preferably between 25-35, however, in the assays carried out, 31 has been determined to be the optimum number.
  • the number of transfers from one syringe (10) to the other syringe (10) in this second process is the same as the number of processes carried out in the first process.
  • the step of transferring fat from one syringe (10) to the other at least 5 times through the space between the blades (121 ) must be repeated two more times. This process is carried out three times in total.
  • the sample can be processed through a fat breaking kit (11 ) having a blade (12) with larger blade spaces (121 ) from those mentioned above.
  • the size of said spaces of the blades can vary between 50-2400pm.
  • the blade spaces can vary between 2400-50 pm, or they can be particularly 600 pm.
  • the size of said blade spaces (121 ) mentioned can vary between 50-3000pm. Preferably the blade spaces can vary between 2400-600 pm. The sizes of the blade spaces (121 ) are particularly between 1200-2400 pm, more specifically between 1800-2400 pm. A blade having blade spaces (121 ) of 2400 pm has been used in the application.
  • the process of transferring from this third syringe (10) to the other syringe (10) can be carried out 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49 or 50 times.
  • the number of the related transfers is preferably between 25-35, however, in the assays carried out, 31 has been determined to be the optimum number.
  • the number of transfers from syringe (10) to the other syringe (10) in this second process is the same as the number of processes carried out in the first process.
  • the number of transfers from one syringe (10) to the other syringe (10) are singular numbers. Every time the tissue is passed through the blades (12) the necrotic tissues accumulate on the blade (12) at the initial side. In the process carried out in singular numbers, the fat tissue is finally filled into the other syringe (10) and due to this reason it comprises a very small amount of necrotic tissue or it may not compare any necrotic tissue.
  • the fat section that is passed from the fat breaking kit (11 ) through the different blade spaces (121 ) three times is collected into a container and preferably ringer lactate or normal saline is added into the container.
  • the ringer lactate or normal saline ratio is approximately 1/8.
  • the container can be selected as a syringe or a tube.
  • the container is preferably shaken for 30-60 seconds.
  • the container is centrifuged.
  • the centrifuge must be carried out with such relative centrifugal force and time that SVF accumulates at the bottom of the container.
  • 400 G relative centrifuge force is applied and the desired results have been obtained from the container that was centrifuged for 10 minutes.
  • SVF that sticks to the bottom of the container is collected after being scraped from the related section with a long needle.
  • said container is selected as a syringe and the bottom (T) section of said syringe is conically shaped.
  • T bottom section of said syringe
  • the SVF that is finally obtained is re-dispersed manually or by vortex and is made ready to be injected.
  • Cell counting is carried out by the application of a staining dye to SVF that turns the live nucleated cells into green and the dead cells into red and by counting the cell numbers with a suitable device.
  • Measurement protocols have been arranged as follows;
  • the nucleated cell numbers obtained by this method vary between 3- 8 million. Particularly in example 3, a conical based structure has been used and as a result, the highest number of core cells have been reached.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • External Artificial Organs (AREA)

Abstract

L'invention concerne un procédé d'isolement de fraction vasculaire stromale provenant d'un tissu adipeux, comprenant les étapes suivantes : l'obtention d'un échantillon contenant des tissus adipeux prélevés sur le donneur ; la centrifugation de l'échantillon jusqu'à la séparation du sang, de la graisse et des triglycérides ; le transfert de la section de graisse dans une seringue ; le raccord de la seringue contenant la graisse avec la seringue du nécessaire de fractionnement de graisse par leurs extrémités de telle sorte que la graisse est transférée d'une seringue à l'autre seringue à travers les lames du nécessaire de fractionnement de graisse, dans lequel l'espace entre lesdites lames est sélectionné pour être compris entre 50 et 2400 microns ; la répétition du procédé susmentionné au moins 5 fois de plus, en faisant passer la graisse d'une seringue à l'autre par l'espace entre les lames et en répétant ce procédé au moins une fois, les espaces entre les lames du nécessaire de fractionnement de graisse diminuant à chaque répétition ; l'agitation respective de la graisse décomposée obtenue et l'application d'un procédé de centrifugation ; la collecte de la fraction vasculaire stromale qui s'accumule au fond du récipient à la fin du procédé de centrifugation.
EP20864767.7A 2019-09-16 2020-04-10 Procédé d'obtention d'une fraction vasculaire stromale Pending EP3876954A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2019/13977A TR201913977A1 (tr) 2019-09-16 2019-09-16 Stromal vasküler fraksi̇yon elde etmek üzere bi̇r yöntem
PCT/TR2020/050306 WO2021054909A1 (fr) 2019-09-16 2020-04-10 Procédé d'obtention d'une fraction vasculaire stromale

Publications (2)

Publication Number Publication Date
EP3876954A1 true EP3876954A1 (fr) 2021-09-15
EP3876954A4 EP3876954A4 (fr) 2022-01-26

Family

ID=74883224

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20864767.7A Pending EP3876954A4 (fr) 2019-09-16 2020-04-10 Procédé d'obtention d'une fraction vasculaire stromale

Country Status (3)

Country Link
EP (1) EP3876954A4 (fr)
TR (1) TR201913977A1 (fr)
WO (1) WO2021054909A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020196A (en) * 1996-05-09 2000-02-01 Baxter International Inc. Devices for harvesting and homogenizing adipose tissue containing autologous endothelial cells
IT1400069B1 (it) * 2010-05-20 2013-05-17 Tremolada Dispositivo e metodo per la preparazione di tessuto, in particolare tessuto adiposo per trapianto ottenuto da materiale adiposo lobulare estratto tramite liposuzione
SG11201600133TA (en) * 2013-07-10 2016-02-26 Agency Science Tech & Res Method for isolating stromal vascular fraction
CN109355251A (zh) * 2018-09-20 2019-02-19 瑞梦德医药科技(北京)有限公司 脂肪组织来源复合细胞群及其制备方法与应用
WO2020101622A1 (fr) * 2018-11-12 2020-05-22 T-Bi̇yoteknoloji̇ Laboratuvar Esteti̇k Medi̇kal Kozmeti̇k San Ti̇c Ltd Şti̇ Kit lame-filtre élaboré pour être utilisé pour le transfert de graisse

Also Published As

Publication number Publication date
WO2021054909A1 (fr) 2021-03-25
TR201913977A1 (tr) 2021-04-21
EP3876954A4 (fr) 2022-01-26

Similar Documents

Publication Publication Date Title
US20220184135A1 (en) Bone Marrow Adipose Portion Isolation Device and Methods
Grisendi et al. GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion
CN102367435B (zh) 人富血小板血浆的制备及在人间充质干细胞分离培养中的应用
CN108025113B (zh) 制备成骨性骨移植物的方法
Palumbo et al. In vitro evaluation of different methods of handling human liposuction aspirate and their effect on adipocytes and adipose derived stem cells
WO2015137419A1 (fr) Activateur de cellules souches mésenchymateuses, cellules mésenchymateuses activées, et leur procédé de production
Smiler et al. Toward the identification of mesenchymal stem cells in bone marrow and peripheral blood for bone regeneration
JP5668075B2 (ja) 幹細胞の分離方法
WO2014036094A1 (fr) Isolation de fraction vasculaire stromale des tissus adipeux, obtenue à l'aide de l'homogénéisation avec des perles
WO2021054909A1 (fr) Procédé d'obtention d'une fraction vasculaire stromale
Herten et al. Bone marrow concentrate for autologous transplantation in minipigs
JP7021109B2 (ja) 非酵素的方法および破砕装置
TWI640625B (zh) 體外快速切碎脂肪組織以分離活細胞之方法
Leonardi et al. Isolation, characterisation and osteogenic potential of human bone marrow stromal cells derived from the medullary cavity of the femur
Dozza et al. A rapid method for obtaining mesenchymal stem cells and platelets from bone marrow aspirate
CA2893828A1 (fr) Isolement et concentration de cellules sanguines sur le lieu d'intervention
JP6061600B2 (ja) 微小幹細胞の分離方法
Mendes et al. Fat grafting: Lipofragmentation x liposuction
Mundy et al. Evaluation of the ability of a gravitational filtration system to enhance recovery of equine bone marrow elements
WO2014152282A1 (fr) Transplantation de fraction vasculaire stromale allogénique par appariement par type de sang
KR101887256B1 (ko) 히알루론산을 이용하여 골수로부터 단핵세포를 분리하는 방법 및 이를 위한 조성물
EP4115918A1 (fr) Système de seringue pour le traitement d'un fluide
Dozza et al. A Novel Mesenchymal Stem Cells and Platelets Concentrate For Bone Reconstruction
Condé-Green et al. Fat Processing Methods
Saadi et al. Upregulation of CD133 and CD44 as Markers of Resident Renal Progenitor Cells Following BM-MSCs Transfusion for Renal Regeneration

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210610

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20220104

RIC1 Information provided on ipc code assigned before grant

Ipc: B01L 3/00 20060101ALI20211221BHEP

Ipc: A61K 35/35 20150101ALI20211221BHEP

Ipc: A61K 35/12 20150101ALI20211221BHEP

Ipc: C12N 5/0775 20100101AFI20211221BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)